Research

Hormonal

Long-term glucocorticoid treatment causes insulin resistance, glucose intolerance, and abnormal weight gain by suppressing osteoblast function and osteocalcin synthesis; disrupting this skeletal signaling pathway prevents these metabolic adverse effects.

This research suggests that the metabolic side effects of long-term glucocorticoid use (like weight gain and insulin resistance) are partly driven by the suppression of bone-derived hormones (osteocalcin). While this is a mouse study, it implies that maintaining bone health or osteocalcin levels might mitigate metabolic risks in patients on steroids, though direct human interventions are not yet established.

GoodSupportsHIGH confidence
Osteoblast-targeted disruption of glucocorticoid signaling significantly attenuated the suppression of osteocalcin synthesis and prevented the development of insulin resistance, glucose intolerance, and abnormal weight gain in corticosterone-treated mice.
Tara C. Brennan‐Speranza et al. · Journal of Clinical Investigation · 2012

Why this rating

High-quality controlled animal study with transgenic models and gene therapy, but results are not directly translatable to human clinical practice without further validation.

Source

Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism

Tara C. Brennan‐Speranza et al. · Journal of Clinical Investigation · 2012

DOI 10.1172/jci63377

mechanism_only · n=60Cited 186×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →